<DOC>
	<DOCNO>NCT01011972</DOCNO>
	<brief_summary>XMT-1107 show nonclinical study slow growth tumor . These effect may result block growth new blood vessel help tumor survive .</brief_summary>
	<brief_title>A Study Intravenous XMT-1107 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This open-label , ascending-dose study XMT-1107 administer intravenously 90 minute every 21 day ( 1 cycle ) . Blood sample PK analysis perform immediately prior dose dosing . Adverse event grade accord National Cancer Institute ( NCI ) Common Terminology Criteria ( CTC ) version 4.0 ( CTCAE v4.0 )</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Patient must histological diagnosis advance solid tumor must refractory standard therapy effective therapy . Measurable evaluable disease . At least 42 day since administration mitomycin nitrosoureas 28 day since chemotherapy , investigational agent , and/or radiation therapy . Age ≥ 18 year old . Have follow laboratory value : Absolute neutrophil count ( ANC ) ≥ 1500 cells/mm3 Platelet count ≥ 100,000 cells/mm3 Hemoglobin ≥ 9 g/dL Serum creatinine ≤ 1.5 mg/dL calculate creatinine clearance ≥ 60 mL/min ( Calculated Cockroft Gault method . Creatinine clearance ( mL/min ) = ( 140age ) x weight ( kg ) /72 x ( serum creatinine mg/dL ) = ml**/min ( **for female , multiply result 0.85 ) ) Total bilirubin ≤ 1.5 mg/dL ≤ upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 time institutional upper limit normal ( ULN ) ≤ 5 time ULN liver metastases present Prothrombin time ( PT ) partial thromboplastin time ( PTT ) ≤ 1.5 time ULN Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 01 . Life expectancy least 3 month . Signed informed write consent . Known brain metastasis ( either currently previously ) . Peripheral neuropathy ≥ Grade 2 . Ataxia ≥ Grade 1 . Cognitive disturbance ≥ Grade 1 . History seizure . Patients know human immunodeficiency virus ( HIV ) positive . Active infection require IV antibiotic serious intercurrent illness , include hepatitis B C. Unstable angina , recent myocardial infarction ( within previous 6 month ) , use ongoing maintenance therapy lifethreatening arrhythmia . Known hypersensitivity class drug . Pregnant nursing woman , woman childbearing potential use effective method either barrier hormonal contraceptive . Men use effective method barrier contraceptive , would willing continue use effective method duration study . Patients major surgical procedure ( include mediastinoscopy ) , open biopsy , significant traumatic injury ≤ 4 week prior begin treatment . Patients proteinuria screen demonstrate either : 1. urine protein creatinine ( UPC ) ratio ≥ 1.0 screening OR 2. urine dipstick proteinuria ≥ 2+ ( patient discover ≥ 2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection , must demonstrate ≤ 1 g protein/24 hour eligible ) Patients serious nonhealing wound , active ulcer , untreated bone fracture . Patients history hematemesis hemoptysis ( define bright red blood ½ teaspoon per episode ) ≤ 1 month prior study enrollment . Inadequately control hypertension ( define systolic blood pressure &gt; 140 mm Hg and/or diastolic blood pressure &gt; 90 mm Hg antihypertensive medication ) . Initiation antihypertensive agent permit provided adequate control document least 1 week prior begin study treatment . Significant vascular disease ( e.g. , aortic aneurysm require surgical repair , recent peripheral arterial thrombosis ) ≤ 6 month prior Day 1 treatment . History stroke transient ischemic attack ≤ 6 month prior begin treatment . Any prior history hypertensive crisis hypertensive encephalopathy . History abdominal fistula gastrointestinal perforation ≤ 6 month prior Day 1 begin treatment . QTc interval &gt; 470 millisecond calculate Bazett 's formula . Any issue , opinion Investigator , would render patient unsuitable study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Dose escalation</keyword>
	<keyword>XMT-1107</keyword>
	<keyword>1107</keyword>
	<keyword>Tumor</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Fumagillol</keyword>
	<keyword>PHF</keyword>
	<keyword>Fleximer</keyword>
	<keyword>cancer</keyword>
	<keyword>maximum tolerate dose</keyword>
	<keyword>MTD</keyword>
</DOC>